Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352550 | 0.79 | CYP3A4 (0.49) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2C19 | |
| Hydrochloric Acid SCHEMBL28284233 | 0.77 | POLB (0.48) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2C19 | |
| Hydrochloric Acid SCHEMBL28255032 | 0.77 | POLB (0.48) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2C19 | |
| SCHEMBL2147364 | 0.75 | CYP3A4 (0.56) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2C19 | |
| SCHEMBL728785 | 0.72 | CYP2D6 (0.49) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL735709 | 0.72 | SIGMAR1 (0.47) | CYP3A4HSD17B10SIGMAR1CYP2C19CYP2D6 | |
| SCHEMBL27657086 | 0.72 | CYP2D6 (0.43) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 | |
| SCHEMBL9721841 | 0.69 | SIGMAR1 (0.45) | CYP3A4HSD17B10SIGMAR1CYP2C19CYP2D6 | |
| SCHEMBL3604123 | 0.69 | SIGMAR1 (0.65) | CYP3A4SIGMAR1CYP2C19CYP2D6BCHE | |
| SCHEMBL9223591 | 0.69 | JAK2 (0.47) | CYP3A4HSD17B10SIGMAR1OPRL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736907-B1 | INDAZOLES | PFIZER LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-8895544-B2 | Indazoles | PFIZER LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| EP-2736907-A1 | INDAZOLES | Pfizer Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20140024634-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| US-8575336-B2 | Indazoles | PFIZER LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| WO-2013014567-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20130029968-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-1636217-B1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-7122545-B2 | Imidazo-benzothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-7091200-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX U.S.A. LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-6900220-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | BECKER CYRUS K (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1363899-B1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-05-11 | — | — | EP | disclosed |
| US-20040229862-A1 | Imidazo-benzothiazoles | F. HOFFMAN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029968-A1 | INDAZOLES | CYP11B2, CYP11B1, IL33 | CYP3A4 13/4885HSD17B10 399/4885SIGMAR1 1808/4885 |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | CYP3A4 135/4885HSD17B10 1376/4885SIGMAR1 18/4885 |
| US-20140024634-A1 | INDAZOLES | JAK1, JAK3, JAK2 | CYP3A4 443/4885HSD17B10 1713/4885SIGMAR1 3568/4885 |
| US-20040229862-A1 | Imidazo-benzothiazoles | ADORA1, ADORA3, ADORA2A | CYP3A4 1063/4885HSD17B10 4200/4885SIGMAR1 39/4885 |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | CYP3A4 135/4885HSD17B10 1463/4885SIGMAR1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.